



This map is a compilation of the biotech's effort to rid the world of COVID-19. Our visualization aims to convey not only individual innovations from specific companies but also the collective effort and sheer hustle of the entire industry. The urgency of COVID-19 has propelled not only new treatments for an acute viral illness but also a greater appreciation of what society can accomplish when we unite against a common foe. We've already achieved remarkable innovations in many diseases: hepatitis C, HIV, melanoma, breast cancer, and cystic fibrosis, to name a few. What we need now is a sustained, collective effort to make medical advances available to everyone instead of overburdening patients with excessive out-of-pocket costs that discourage them from receiving appropriate care. This will require fundamentally reforming America's insurance system. Building on the recent patches put in place after payers initially refused to cover COVID-19 testing and the uninsured were penalized by the cost of hospitalization. The Biotech Social Contract, as described in The Great American Drug Deal, affirms that we do not have to choose between innovation and affordability. We as a society can rise to the challenge of tackling all human diseases just as we have COVID-19, tracking investments that will permanently upgrade our health and that of future generations.



MAP LEGEND

This version of RA Capital's COVID-19 map is out of date.

Please visit:

WWW.RACAP.COM/COVID-19 >

to view the latest version of the map



DISCLAIMER RA Capital Management, LP ("RA Capital") is an investment advisor registered with the Securities and Exchange Commission ("SEC") under the Investment Advisers Act of 1940, as amended ("Advisers Act").